Novartis Says New Mayzent Data Shows Sustained Effect In Delaying Disability
Novartis announced new Mayzent (siponimod) data in the April supplemental issue of Neurology, the medical journal of the American Academy of Neurology. The data build on existing…
Read More...
Read More...
